Teriparatide
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| Teriparatide
| |
| Systematic (IUPAC) name | |
| ? | |
| Identifiers | |
| CAS number | ? |
| ATC code | H05 |
| PubChem | |
| Chemical data | |
| Formula | C181H291N55O51S2 |
| Mol. mass | 4117.72 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 95% |
| Metabolism | Hepatic (nonspecific proteolysis) |
| Half life | SubQ: 1 hour |
| Excretion | Renal (metabolites) |
| Therapeutic considerations | |
| Pregnancy cat. |
C |
| Legal status | |
| Routes | SubQ |
|
WikiDoc Resources for Teriparatide | |
|
Articles | |
|---|---|
|
Most recent articles on Teriparatide Most cited articles on Teriparatide | |
|
Media | |
|
Powerpoint slides on Teriparatide | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Teriparatide at Clinical Trials.gov Clinical Trials on Teriparatide at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Teriparatide
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Teriparatide Discussion groups on Teriparatide Patient Handouts on Teriparatide Directions to Hospitals Treating Teriparatide Risk calculators and risk factors for Teriparatide
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Teriparatide | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Teriparatide (Forteo®) is a recombinant form of parathyroid hormone, used in the treatment of advanced osteoporosis. It is manufactured and marketed by Eli Lilly and Company.
Administration
Teriparatide is administered by injection once a day in the thigh or abdomen. The recommended dose is 20 μg per day.
Uses
Teriparatide has recently been given to patients in an ongoing clinical trial to evaluate its effectiveness in treating the symptoms of osteogenesis imperfecta.[1]
Teriparatide should not be prescribed for patients who are at increased risks for osteosarcoma. This includes those with Paget's Disease of bone or unexplained elevations of serum alkaline phosphate, open epiphysis, or prior radiation therapy involving the skeleton.
Mechanism of action
Teriparatide is the portion of human parathyroid hormone (PTH),amino acid sequence 1 through 34 of the complete molecule which contains amino acid sequence 1 to 84. Endogenous PTH is the primary regulator of calcium and phosphate metabolism in bone and kidney. Daily injections of teriparatide stimulate new bone formation leading to increased bone mineral density.
Teriparatide is the first FDA approved agent for the treatment of osteoporosis that stimulates new bone formation.
FDA approval
Teriparatide was approved by the Food and Drug Administration (FDA) on 26 November, 2002, for the treatment of osteoporosis in men and postmenopausal women who are at high risk for having a fracture. The drug is also approved to increase bone mass in men with primary or hypogonadal osteoporosis who are at high risk for fracture.
References
External links
Calcium homeostasis (H05) | |
|---|---|
| Parathyroid hormones and analogues | Teriparatide |
| Calcitonin preparations | Elcatonin - Cinacalcet |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
